NCT01518894

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Biogen · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and tolerability of multiple, ascending doses of PF-04958242 administered orally to psychiatrically stable subjects with schizophrenia receiving antipsychotic and adjunctive medication.

Detailed description

This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	PF-04958242	PF-04958242 0.10 mg oral solution Q24 hours for 14 days
DRUG	PF-04958242	PF-04958242 0.20 mg oral solution Q24 hours for 14 days
DRUG	PF-04958242	PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
DRUG	Placebo	Placebo oral solution Q24 hours for 14 days

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2012-01-26
• Last updated: 2019-11-21

Locations

1 site across 1 country: United States